Effects of intermediate-conductance Ca2+-activated K+ channel modulators on human prostate cancer cell proliferation

European Journal of Pharmacology

Volumn 471, Issue 3, 2003, Pages 157-164

  Parihar, Ashutosh S ^a   Coghlan, Michael J ^a   Gopalakrishnan, Murali ^a   Shieh, Char Chang ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

1 EBIO; Benign prostatic hyperplasia; Intermediate conductance K+ channel, intermediate conducting, Ca2+ activated; LNCaP; PC 3; Riluzole

Indexed keywords

1 ETHYL 2 BENZIMIDAZOLINONE; 2 AMINO 5 (2 FLUOROPHENYL) 4 METHYL 1H PYRROLE 3 CARBONITRILE; APAMIN; CALCIUM ACTIVATED POTASSIUM CHANNEL; CHARYBDOTOXIN; CLOTRIMAZOLE; IBERIOTOXIN; IMIDAZOLINE DERIVATIVE; LEIUROTOXIN I; N [3 (TRIFLUOROMETHYL)PHENYL] N' (2 HYDROXY 5 CHLOROPHENYL)UREA; NS 1608; NS 8; RILUZOLE; RUBIDIUM 86; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; DRUG SENSITIVITY; EVALUATION; EVOKED RESPONSE; HUMAN; HUMAN CELL; INHIBITION KINETICS; ION CONDUCTANCE; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY MECHANISM;

EID: 0038433331     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01825-9     Document Type: Article

References (35)

1. Berry S.J., Coffey D.S., Walsh P.C., Ewing L.L. The development of human benign prostatic hyperplasia with age. J. Urol. 132:1984;474-479.
2. Coghlan M.J., Carroll W.A., Gopalakrishnan M. Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress. J. Med. Chem. 44:2001;1-27.
3. + channel alpha-subunit genes in rat and human prostate cancer cell lines. Prostate. 48:2001;165-178.
4. Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 47:1996;S233-S241.
5. Fanger C.M., Rauer H., Neben A.L., Miller M.J., Wulff H., Rosa J.C., Ganellin C.R., Chandy K.G., Cahalan M.D. Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels. J. Biol. Chem. 276:2001;12249-12256.
6. Foster C.S., Cornford P., Forsyth L., Djamgoz M.B., Ke Y. The cellular and molecular basis of prostate cancer. BJU Int. 83:1999;171-194.
7. Fraser S.P., Grimes J.A., Djamgoz M.B. Effects of voltage-gated ion channel modulators on rat prostatic cancer cell proliferation: comparison of strongly and weakly metastatic cell lines. Prostate. 44:2000;61-76.
8. Ghanshani S., Wulff H., Miller M.J., Rohm H., Neben A., Gutman G.A., Cahalan M.D., Chandy K.G. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J. Biol. Chem. 275:2000;37137-37149.
9. + current expressed in the highly metastatic Mat-LyLu cell line of rat prostate cancer. J. Cell. Physiol. 175:1998;50-58.
10. Grunnet M., Jespersen T., Angelo K., Frokjaer-Jensen C., Klaerke D.A., Olesen S.P., Jensen B.S. Pharmacological modulation of SK3 channels. Neuropharmacology. 40:2001;879-887.
11. Hebert T., Drapeau P., Pradier L., Dunn R.J. Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol. Pharmacol. 45:1994;1055-1060.
12. Ishii T.M., Silvia C., Hirschberg B., Bond C.T., Adelman J.P., Maylie J. A human intermediate conductance calcium-activated potassium channel. Proc. Natl. Acad. Sci. U. S. A. 94:1997;11651-11656.
13. + channel. Am. J. Physiol. 275:1998;C848-C856.
14. + channel activity in human prostate cancer cell lines of markedly different metastatic potential: distinguishing characteristics of PC-3 and LNCaP cells. Prostate. 46:2001;262-274.
15. 2+-ATPases 2B involvement in human prostate cancer cell growth control. J. Biol. Chem. 276:2001;47608-47614.
16. Lindzey J., Grossmann M., Kumar M.V., Tindall D.J. Regulation of the 5′-flanking region of the mouse androgen receptor gene by cAMP and androgen. Mol. Endocrinol. 7:1993;1530-1540.
17. Logsdon N.J., Kang J., Togo J.A., Christian E.P., Aiyar J. A novel gene, hKCa4, encodes the calcium-activated potassium channel in human T lymphocytes. J. Biol. Chem. 272:1997;32723-32726.
18. Ca channels that hyperpolarize the membrane and enhance calcium influx. J. Gen. Physiol. 113:1999;81-96.
19. Mizokami A., Saiga H., Matsui T., Mita T., Sugita A. Regulation of androgen receptor by androgen and epidermal growth factor in a human prostatic cancer cell line, LNCaP. Endocrinol. Jpn. 39:1992;235-243.
20. Nakhla A.M., Bardin C.W., Salomon Y., Mather J.P., Janne O.A. The actions of calcitonin on the TM3 Leydig cell line and on rat Leydig cell-enriched cultures. J. Androl. 10:1989;311-320.
21. Ca channel diversity and smooth muscle cell function. Circ. Res. 85:1999;e33-e43.
22. Parihar A.S., Zhang X.F., Whiteaker K.L., Davis-Taber R., Scott V.E.S., Coghlan M., Gopalakrishnan M., Shieh C.-C. Effect of potassium channel modulators on human prostate clonal cells. Soc. Neurosci. 26:2001;A-272.19.
23. 2+-dependent. Biochim. Biophys. Acta. 1420:1999;231-240.
24. Rane S.G. The growth regulatory fibroblast IK channel is the prominent electrophysiological feature of rat prostatic cancer cells. Biochem. Biophys. Res. Commun. 269:2000;457-463.
25. Shieh C.-C., Coghlan M., Sullivan J.P., Gopalakrishnan M. Potassium channels: molecular defects, disease, and therapeutic opportunities. Pharmacol. Rev. 52:2000;557-593.
26. Skryma R.N., Prevarskaya N.B., Dufy-Barbe L., Odessa M.F., Audin J., Dufy B. Potassium conductance in the androgen-sensitive prostate cancer cell line, LNCaP: involvement in cell proliferation. Prostate. 33:1997;112-122.
27. Smith P., Rhodes N.P., Shortland A.P., Fraser S.P., Djamgoz M.B., Ke Y., Foster C.S. Sodium channel protein expression enhances the invasiveness of rat and human prostate cancer cells. FEBS Lett. 423:1998;19-24.
28. + channels. Am. J. Physiol. Cell. Physiol. 278:2000;C570-C581.
29. White R.E., Lee A.B., Shcherbatko A.D., Lincoln T.M., Schonbrunn A., Armstrong D.L. Potassium channel stimulation by natriuretic peptides through cGMP-dependent dephosphorylation. Nature. 361:1993;263-266.
30. Wilson T.M., Yu-Lee L.Y., Kelley M.R. Coordinate gene expression of luteinizing hormone-releasing hormone (LHRH) and the LHRH-receptor after prolactin stimulation in the rat Nb2 T-cell line: implications for a role in immunomodulation and cell cycle gene expression. Mol. Endocrinol. 9:1995;44-53.
31. Woolf S.H. Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N. Engl. J. Med. 333:1995;1401-1405.
32. Wu S.N., Li H.F. Characterization of riluzole-induced stimulation of large-conductance calcium-activated potassium channels in rat pituitary GH3 cells. J. Investig. Med. 47:1999;484-495.
33. Xu L., Enyeart J.A., Enyeart J.J. Neuroprotective agent riluzole dramatically slows inactivation of Kv1.4 potassium channels by a voltage-dependent oxidative mechanism. J. Pharmacol. Exp. Ther. 299:2001;227-237.
34. Xue Y., Smedts F., Verhofstad A., Debruyne F., De La Rosette J., Schalken J. Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: new perspectives. Prostate, Suppl. 8:1998;62-73.
35. Zona C., Siniscalchi A., Mercuri N.B., Bernardi G. Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons. Neuroscience. 85:1998;931-938.